US · Healthcare · Biotechnology
EPS came in at -0.52 against a street estimate of -0.55 — a beat of 5.5%.
Analysts rate Cogent Biosciences Inc a strong buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $55.82.
| Fund | Stake |
|---|---|
| FMR Inc | 14.80% |
| BlackRock Inc | 10.00% |
| Vanguard Portfolio Management, LLC | 4.65% |
| Vanguard Capital Management, LLC | 4.27% |
| State Street Corp | 4.01% |
| Jupiter Topco LLC | 3.82% |
| Fairmount Funds Management LLC | 3.17% |
| Deerfield Management Co | 2.88% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. • F | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net loss was $111.4 million, compared with $80.9 million in Q3 2025. • Total operating expenses were $117.2 million, up f | 2026-11-05 |
| Material agreement · Q3 2026 COGENT BIOSCIENCES, INC. - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Cogent Biosciences entered into a Commercial Supply Agreement with Hovione Fa | 2026-09-02 |
| Quarterly report · Q2 2026 COGENT BIOSCIENCES, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS Q2 2026 (Six Months Ended June 30, 2026) --- HEADLINE NUMBERS • Cash & Securities Posi | 2026-08-10 |
| Company announcement · Q3 2026 COGENT BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company filed prospectus supplement on August 10, 2026 to offer and sell up to $400,000,00 | 2026-08-10 |
| Results announced · Q3 2026 COGENT BIOSCIENCES Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $792.3 million in cash, cash equivalents and marketable securities as | 2026-08-10 |
| Shareholder vote results · Q2 2026 COGENT BIOSCIENCES, INC. – 8-K SUMMARY HEADLINE NUMBERS • As of April 13, 2026 (record date), company had 170,801,004 shares of common stock outstan | 2026-06-11 |
| Quarterly report · Q1 2026 COGENT BIOSCIENCES, INC. — FORM 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash & Liquid Assets: $241.2 million cash + $625.2 million short-term mark | 2026-05-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Manufacturing supply agreement entered into for bezuclastinib products Cogent Biosciences signed a manufacturing supply agreement with Hovione FarmaCiencia on September 1, 2026, to produce bezuclastinib in two forms: spray-dried dispersion and tablets. This is | 2026-09-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cogent Biosciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.